Applications of fluorescence in the characterization of the ligand-binding domain and activation of the cholecystokinin receptor

被引:4
|
作者
Harikumar, KG [1 ]
Miller, LJ [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA
来源
PHARMACOLOGY & TOXICOLOGY | 2002年 / 91卷 / 06期
关键词
D O I
10.1034/j.1600-0773.2002.910604.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fluorescence techniques can be applied to guanine nucleotide-binding protein-coupled receptors to gain insights into the environment and molecular motion of a fluorophore that is either incorporated into a ligand or more directly into a specific site within the receptor. Fluorescence studies can provide insight into the environment of that indicator. By situating the same indicator into an analogous position in both agonist and antagonist ligands. comparisons can provide insights into differences between active and inactive states of the receptor. These types of studies haw been performed for the cholecystokinin receptor and show that receptor activation by agonist occupation is associated with a movement of the CCK-like ligand out of a protected environment and into a more accessible hydrophilic milieu.
引用
收藏
页码:286 / 289
页数:4
相关论文
共 50 条
  • [21] The Hidden Energetics of Ligand-Binding and Activation in a Glutamate Receptor
    Lau, Albert Y.
    Blachowicz, Lydia
    Roux, Benoit
    BIOPHYSICAL JOURNAL, 2011, 100 (03) : 268 - 268
  • [22] Characterization of ligand-binding properties of the human BMP type II receptor extracellular domain
    Yin, Huiran
    Yeh, Lee-Chuan C.
    Hinck, Andrew P.
    Lee, John C.
    JOURNAL OF MOLECULAR BIOLOGY, 2008, 378 (01) : 191 - 203
  • [23] Characterization of the functional role of the N-glycans in the AMPA receptor ligand-binding domain
    Pasternack, A
    Coleman, SK
    Féthière, J
    Madden, DR
    LeCaer, JP
    Rossier, J
    Pasternack, M
    Keinänen, K
    JOURNAL OF NEUROCHEMISTRY, 2003, 84 (05) : 1184 - 1192
  • [24] Separable features of the ligand-binding domain determine the differential subcellular localization and ligand-binding specificity of glucocorticoid receptor and progesterone receptor
    Wan, YH
    Coxe, KK
    Thackray, VG
    Housley, PR
    Nordeen, SK
    MOLECULAR ENDOCRINOLOGY, 2001, 15 (01) : 17 - 31
  • [25] Azoospermia associated with a mutation in the ligand-binding domain of an androgen receptor displaying normal ligand binding, but defective trans-activation
    Wang, Q
    Ghadessy, FJ
    Trounson, A
    de Kretser, D
    McLachlan, R
    Ng, SC
    Yong, EL
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (12): : 4303 - 4309
  • [26] Co-repressor release but not ligand binding is a prerequisite for transcription activation by human retinoid acid receptor α ligand-binding domain
    Kao, HY
    Han, CC
    Korma, AA
    Evans, RM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (09) : 7366 - 7373
  • [27] FLUORESCENCE DISPLACEMENT METHOD FOR THE DETERMINATION OF RECEPTOR LIGAND-BINDING CONSTANTS
    KUZMIC, P
    MOSS, ML
    KOFRON, JL
    RICH, DH
    ANALYTICAL BIOCHEMISTRY, 1992, 205 (01) : 65 - 69
  • [28] Characterization of the ligand-binding site of the rat urotensin receptor
    Krause, G
    Furkert, J
    Beyermann, M
    van der Giet, M
    Zidek, W
    Rosenthal, W
    Oksche, A
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2006, 372 : 33 - 33
  • [29] Interaction of the phosphorylated DNA-binding domain in nuclear receptor CAR with its ligand-binding domain regulates CAR activation
    Shizu, Ryota
    Min, Jungki
    Sobhany, Mack
    Pedersen, Lars C.
    Mutoh, Shingo
    Negishi, Masahiko
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2018, 293 (01) : 333 - 344
  • [30] Folding requirements of the ligand-binding domain of the human mineralocorticoid receptor
    Couette, B
    Jalaguier, S
    Hellal-Levy, C
    Lupo, B
    Fagart, J
    Auzou, G
    Rafestin-Oblin, ME
    MOLECULAR ENDOCRINOLOGY, 1998, 12 (06) : 855 - 863